CRISPR Therapeutics partners with siRNA company, showing that gene editing...
The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood...
View ArticleUpdated: FDA adcomm splits votes on Genentech and J&J cancer drugs
The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. In the afternoon session,...
View ArticleVinay Prasad makes first major imprint on FDA with new vaccine policy
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines that he feels will counteract existing “dogma.”...
View ArticleUK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates
The "healthy lifespan" space is attracting more dollars. Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup,...
View ArticleReproductive health biotech ReproNovo closes $65M Series A
A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall...
View ArticleAltos Labs buys anti-aging startup Dorian Therapeutics
Altos Labs, the massive but still relatively secretive $3 billion biotech, has forged a small acquisition of a startup seeking to reverse aging. Altos, led by industry stalwarts Hal Barron and Hans ...
View ArticleHow PureTech’s lung fibrosis drug stacks up against the competition
PureTech Health’s tweaked form of Roche’s lung fibrosis drug Esbriet slowed lung function decline by a greater degree than Esbriet itself, with comparable safety, the company said Tuesday. On a cross ...
View ArticleGenentech expands partnership with molecular glue biotech Orionis
Roche’s subsidiary Genentech is signing a second deal with Orionis Biosciences to expand its search through the world of protein interactions in hopes of developing new cancer drugs. The two companies...
View ArticleResearchers reveal mixed results from vaccine for cocaine addiction
Scientists from Weill Cornell Medicine in New York have announced the results from a long-awaited but small study of a vaccine designed to soak up cocaine molecules and help people addicted to the...
View ArticleModerna pulls application for Covid-flu shot; Another IPO in Hong Kong
Plus, news about Genfit, Ipsen, Accropeutics, Merck KGaA, Alumis and Acelyrin: Moderna pulls BLA for its Covid-flu shot: The company suggested on its most recent earnings call earlier this month that...
View ArticleBiotech downturn exposes startups to big lease liabilities
For some biotechs, the office is a place where scientists gather and pipelines advance. For others, it’s a boat anchor dragging them to the bottom of the sea. Four years into the biotech downturn, some...
View ArticleBioNTech invests £1B in growing UK footprint under expanded pact with government
BioNTech is spending up to £1 billion over the next ten years to boost its R&D activities in the UK as part of an enhanced agreement with the UK government. The government is supplying BioNTech ...
View ArticleFDA adcomm narrowly votes against UroGen’s bladder cancer drug
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen Pharma's mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer. Panelists and...
View ArticleEikon Therapeutics cuts staff following $351M Series D
Eikon Therapeutics is laying off staff for the second time in 19 months, responding to “changes in external circumstances” that have created “financial challenges.” That was the rationale relayed to...
View ArticleTeva, Novartis get new FTC warnings over Orange Book listings
The FTC is continuing its campaign against drug patents that it claims are improperly listed in an FDA database known as the Orange Book, carrying over an approach started under the Biden...
View ArticleFDA announces efforts to facilitate drug importation from Canada
The FDA said it is making “enhancements” designed to help states develop programs for importing cheaper drugs from Canada. The move follows an April 15 executive order directing HHS Secretary Robert ...
View ArticleFDA asks Covid vaccine makers to add more myocarditis data to labels
The FDA has asked for two Covid-19 vaccines made by Moderna and Pfizer/BioNTech to include new safety warnings on a type of heart risk, according to letters posted by the agency. The FDA asked the ...
View ArticleHinge Health prices IPO at $32 a share, $3B valuation
Hinge Health priced its shares at $32 per share, valuing the virtual physical therapy startup at around $3 billion in a closely watched debut for the health tech industry. The share price is on the ...
View ArticleFDA adcomm votes unanimously against Pfizer's prostate cancer drug combo
The FDA’s Oncologic Drugs Advisory Committee voted 8-0 against a new indication for Pfizer’s Talzenna in combination with Xtandi for first-line treatment of adults with non-homologous recombination...
View Article